XNASELVN
Market cap1.09bUSD
Dec 27, Last price
22.37USD
1D
-1.50%
1Q
-7.29%
IPO
-65.05%
Name
Enliven Therapeutics Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
52.43%
Rev. gr., 5y
%
Revenues
0k
Net income
-72m
L+89.63%
CFO
-61m
L+91.01%
Earnings
Mar 12, 2025
Profile
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
IPO date
Mar 12, 2020
Employees
37
Domiciled in
US
Incorporated in
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | 83,826 | 39,413 | 24,861 | ||||
Unusual Expense (Income) | |||||||
NOPBT | (83,826) | (39,413) | (24,861) | ||||
NOPBT Margin | |||||||
Operating Taxes | 88 | (22) | |||||
Tax Rate | |||||||
NOPAT | (83,826) | (39,501) | (24,839) | ||||
Net income | (71,584) 89.63% | (37,750) 52.72% | (24,718) 30.54% | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 161,201 | 591 | 464 | ||||
BB yield | -32.77% | -1.16% | -2.24% | ||||
| Debt | |||||||
Debt current | 335 | 323 | 159 | ||||
Long-term debt | 335 | 323 | 159 | ||||
Deferred revenue | |||||||
Other long-term liabilities | 67 | 150,408 | 150,463 | ||||
Net debt | (252,478) | (74,944) | (109,881) | ||||
| Cash flow | |||||||
Cash from operating activities | (61,269) | (32,077) | (19,134) | ||||
CAPEX | (149) | (612) | (191) | ||||
Cash from investing activities | (148,412) | (612) | (191) | ||||
Cash from financing activities | 234,286 | (1,799) | (1,016) | ||||
FCF | (83,372) | (40,063) | (25,377) | ||||
| Balance | |||||||
Cash | 253,148 | 75,536 | 110,024 | ||||
Long term investments | 54 | 175 | |||||
Excess cash | 253,148 | 75,590 | 110,199 | ||||
Stockholders' equity | (154,266) | (82,863) | (45,067) | ||||
Invested Capital | 400,574 | 156,769 | 152,802 | ||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | 35,546 | 3,124 | 2,306 | ||||
Price | 13.84 -15.40% | 16.36 81.78% | 9.00 -89.80% | ||||
Market cap | 491,960 862.49% | 51,113 146.27% | 20,755 -93.24% | ||||
EV | 239,482 | (23,681) | (88,976) | ||||
EBITDA | (83,529) | (39,198) | (24,746) | ||||
EV/EBITDA | 0.60 | 3.60 | |||||
Interest | 1,217 | ||||||
Interest/NOPBT | |||||||